Biomarker-Guided Strategies in Esophagogastric Cancer: Module 1 With Dr. Yelena Janjigian скачать в хорошем качестве

Biomarker-Guided Strategies in Esophagogastric Cancer: Module 1 With Dr. Yelena Janjigian

Complete the activity and claim your credit today: https://bit.ly/4mx0ECQ Complete Module 2 here:    • Optimizing Esophagogastric Cancer Treatmen...   Esophagogastric cancers are the second leading cause of cancer-related deaths worldwide. In Module 1 of this podcast, Dr. Yelena Y. Janjigian, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, explores biomarker-guided approaches in esophagogastric cancer management. Learn about key biomarkers like HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2, and how they are transforming treatment selection and advancing care for patients with advanced gastric and gastroesophageal junction cancers. Follow us here: Facebook   / i3health   Instagram   / i3health   Linkedin   / i3health   Soundcloud   / i3-health   X   / i3health   STATEMENT OF NEED Esophagogastric cancers, including cancers of the esophagus, stomach, and gastroesophageal junction, represent the second most common cause of cancer-related deaths worldwide. In recent years, the treatment landscape of esophagogastric cancer has seen significant progress with the identification of novel biomarkers, including HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2, which are now used to guide treatment selection. Numerous novel targeted agents are being investigated in clinical trials, and HER2-targeted therapies and immunotherapies are approved for patients with advanced gastric and gastroesophageal junction cancers (Yu & Mehta, 2025). Therefore, it is crucial for members of the interdisciplinary cancer care team to remain up-to-date on biomarker testing methods and considerations for treatment selection. In Module 1 of this podcast, Yelena Y. Janjigian, MD, Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, will discuss biomarker-guided approaches in esophagogastric cancer management. DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Yelena Y. Janjigian, MD, discloses that she has served on an advisory board or panel or as a consultant for AbbVie, Amerisource Bergen, Ask-Gene Pharma, Arcus Biosciences, Astellas, AstraZeneca, Basilea Pharmacutica, Bayer, BeOne, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, Geneos Therapeutics, Gilead Sciences, GlaxoSmithKline, Guardant Health, Health Advances, HMP Global, Imedex, Imugene, Inspirna, Lynx Health, Mashup Media, Master Clinician Alliance, Merck, Merck Serono, Mersana Therapeutics, PeerMD, Pfizer, Sanofi Genzyme, Seagen, Silverback Therapeutics, Suzhou Liangyihui Network Technology Co. Ltd., and Zymeworks; that she has received research funding from Astellas, AstraZeneca, Arcus Biosciences, Bayer, Bristol Myers Squibb, Cycle for Survival, Eli Lilly, Genentech/Roche, Inspirna, Merck, and Trascenta; and that she has is a stock/shareholder of Inspirna and Veda Life Sciences, Inc. i3 Health has mitigated all relevant financial relationships. #EsophagogastricCancer #BiomarkerTesting #OncologyInnovation #HER2 #Immunotherapy #GastrointestinalOncology #TargetedTherapies #OncologyEducation #CancerCare